Andrew Tsai

Julian Pino

Myles Minter

Elena Bidros

John Boyle

Jo Yi Chudy

Lin Tsai

Madison El-Saadi

Madison Wynne El-Saadi

Matthew Barcus

Tim Lugo

- Vistagen Therapeutics is a **late-stage, clinical-stage company** leveraging nose-to-brain neurocircuitry with neuroactive pherines, with its lead program, fasedienol, targeting the acute treatment of social anxiety disorder (SAD).  **[1411685_2147478_0]** 
- The fasedienol program has demonstrated **positive Phase III results in PALISADE-2**.  **[1411685_2147478_2]**  The company anticipates results for **PALISADE-3 in Q4 2025** and for **PALISADE-4 in the first half of 2026**.  **[1411685_2147478_7]** 
- Fasedienol's unique mechanism of action involves modulating olfactory-limbic-amygdala fear and anxiety neural circuits without systemic absorption, leading to a **rapid onset of benefit and a remarkable safety profile**.  **[1411685_2147478_0]** **[1411685_2147478_1]** 
- Vistagen identifies a **significant market opportunity** for fasedienol, noting that approximately 30 million U.S. adults are affected by SAD, with only about 30% currently receiving treatment.  **[1411685_2147478_10]**  The drug is positioned as a PRN (as needed) treatment without the typical side effects of existing options.  **[1411685_2147478_6]** **[1411685_2147478_10]** 
- Beyond fasedienol, the company's pipeline includes **PH80 for menopausal hot flashes**, with an Investigational New Drug (IND) application expected in Q4 2025, and **iTRUVON for major depressive disorder**.

Vistagen Therapeutics Discusses Fasedienol Program and Pipeline Updates

Vistagen Therapeutics (VTGN)